Akesis Pharmaceuticals Inc.

Prior to joining Akesis Pharmaceuticals in December 2004, Mr. Hendrick was primarily engaged in monitoring his private equity investments since July 2001. From July 1996 to December 1999 he was vice chairman and chief financial officer of The Cassidy Companies, Inc., one of the largest government and public affairs firms in Washington, DC. He was also a managing director of Galway Partners, LLC, a Washington, DC-based merchant bank, from July 1996 to June 2001. Prior to joining Cassidy and Galway in 1996, Mr. Hendrick was a general partner with Avalon Ventures, a San Diego-based venture capital firm, from 1987 to 1996. In addition, Mr. Hendrick serves on the investment committees of Innova Capital (formerly Poland Partners), a Warsaw-based venture capital fund, and Taiwan-based venture capital funds Taiwan Mezzanine Fund and Greater China Private Equity Fund. Mr. Hendrick is a certified public accountant and earned a B.B.A. degree in Accounting from McMurry University in 1973.

Kevin Kinsella has been in the venture capital industry since 1983 when he founded Avalon Ventures. Mr. Kinsella has specialized in the formation, financing and development of more than 60 early stage companies. He is Director of Akesis Pharmaceuticals and a number of private companies. Mr. Kinsella is chairman of the investment committee of Poland Partners and INNOVA 98, respectively a $62.5 million and a $125 million fund investing in Central Europe. Mr. Kinsella is a graduate of the Massachusetts Institute of Technology (1967) with a Bachelor of Science degree in Management, with minors in Electrical Engineering and Political Science. He holds a Master of Arts degree in International Relations from the Johns Hopkins School of Advanced International Studies (SAIS) (1969) and did post-graduate work in political economics on a Rotary International Fellowship at the University of Stockholm, Sweden. Mr. Kinsella is a Life Sustaining Fellow at the Massachusetts Institute of Technology. He is a member of the Council on Foreign Relations, the Dean's Advisory Counsel at SAIS and a Vice-President of the Board of Trustees of the San Diego Museum of Art. He is the largest producer of the Tony Award Winning, hit Broadway musical, Jersey Boys.

Realizing the need for a curative therapy for Type I insulin dependent diabetes was the impetus for the organization of MicroIslet Inc. and the alliance with Duke Medical School in 1998. Mr. Steel serves as the Director of Corporate Development of MicroIslet Inc. Beginning in 1995, Mr. Steel began to pursue interests in the field of Diabetes, a disease that he has had since 1982. He is a Founder and Director of AKESIS Pharmaceuticals, which has developed a patented treatment for insulin resistance for Type II diabetes. Clinical trials were completed in 1999. Mr. Steel was a founder of Defined Benefit Inc. in 1983. The company provided financial services to health care professionals. Mr. Steel sold his share of the company in 1988. From 1989 to 1994, Mr. Steel consulted with several public and private companies on business issues related to distribution of goods, services, and finances. This effort was conducted through Steel Management. Mr. Steel received his MBA degree with an emphasis in finance from the University of Southern California and a Bachelor of Arts degree in Economics from Dartmouth College.